

IV Simposio sobre **Trastorno** **Límite de la Personalidad**

**Tratamiento a largo plazo.
¿Podemos ser optimistas?**

Dr Miquel Gasol

Institut Trastorn Limit, Hospital General de Catalunya, Barcelona

Borderline personality disorder

Klaus Lieb, Mary C Zanarini, Christian Schmahl, Marsha M Linehan, Martin Bohus

Lancet 2004; 364: 453-61

Panel: DSM-IV criteria for borderline personality disorder*

Affective criteria

- Inappropriate intense anger or difficulty controlling anger—eg, frequent displays of temper, constant anger, recurrent physical fights
- Chronic feelings of emptiness
- Affective instability due to a marked reactivity of mood—eg, intense episodic dysphoria, irritability, or anxiety usually lasting a few hours and only rarely more than a few days

Cognitive criteria

- Transient stress-related paranoid ideation or severe dissociative symptoms
- Identity disturbance: striking and persistent unstable self-image or sense of self

Behavioural criteria (forms of impulsivity)

- Recurrent suicidal behaviour, gestures, or threats, or self-mutilating behaviour
- Impulsivity in at least two areas that are potentially self-damaging that do not include suicidal or self-mutilating behaviour

Interpersonal criteria

- Frantic efforts to avoid real or imagined abandonment that do not include suicidal or self-mutilating behaviour
- A pattern of unstable and intense interpersonal relationships characterised by alternating between extremes of idealisation and devaluation





Figure: Neurobehavioural model of borderline personality disorder

Curso longitudinal del TLP

Tiempo para la recuperación parcial, total y recaídas



^a Remission is defined as no longer meeting DSM-III-R and Revised Diagnostic Interview for Borderlines criteria for borderline personality disorder for at least 2 years, and sustained remission as no longer meeting criteria for at least 4 years. Recovery is defined as having remission of symptoms and having good social and vocational functioning during the previous 2 years.


Curso longitudinal de la psicopatología límite: seis años de seguimiento

Remisión: 34,5% a 2 años, 49,4% a 4 años, 68,6% a los
Recurrencias: 6% a los 4 años, 4,6% a los 6 años (5,9% en total)

Reducción de síntomas de manera diferenciada a lo largo del tiempo:

- 1. Manifestaciones agudas** (remisión a los 2 años): automutilación, intentos de suicidio, pensamientos casi psicótico, las regresiones del tratamiento y los problemas de controtransferencia,
- 2. Aspecto temperamental o resistente** (persisten a los 6 años): sentimientos crónicos de vacío o cólera, desconfianza, dificultad para tolerar la soledad y preocupaciones de sufrir de abandono

Curso longitudinal de la psicopatología límite: seis años de seguimiento



Curso longitudinal de la psicopatología límite: 10 años de seguimiento

Tiempo medio de remisión de los 24 síntomas del TLP en 290 pacientes.

Symptoms and Median Time to Remission

0–2 years

- Quasi-psychotic thought
- Sexual deviance
- Treatment regressions
- Countertransference problems/"special" treatment relationships

2–4 years

- Substance abuse/dependence
- Self-mutilation
- Manipulative suicide efforts
- Demandingness/entitlement
- Serious identity disturbance

4–6 years

- Odd thinking/unusual perceptual experiences
- Nondelusional paranoia
- Abandonment/engulfment/annihilation concerns
- Stormy relationships
- Devaluation/manipulation/sadism
- Affective instability

6–8 years


- Chronic/major depression
- Chronic feelings of helplessness/hopelessness/worthlessness/guilt
- Chronic anxiety
- General impulsivity
- Intolerance of aloneness
- Counterdependency/serious conflict over help/care
- Dependency/masochism

8–10 years

- Chronic anger/frequent angry acts
- Chronic loneliness/emptiness

Curso longitudinal de la psicopatología límite: 10 años de seguimiento

FIGURE 1. Percentage of Patients With Borderline Personality Disorder and Comparison Patients With Other Axis II Disorders Who Retained Three Acute and Three Temperamental Borderline Symptoms From Baseline Through Five 2-Year Follow-Up Periods



Curso longitudinal de la psicopatología límite: 10 años de seguimiento




Figure 2. Prevalence of borderline personality disorder criteria. Positive indicates the cases with a score of 2 (definitely present and clinically significant) for each of the 9 borderline personality disorder criteria on the Diagnostic Interview for *DSM-IV* Personality Disorders, assessed for the 2 years prior to the follow-up point.

Curso longitudinal de la psicopatología límite: 10 años de seguimiento

Remisión funcional (GAF > 70 durante 2 meses)




Figure 4. Functional remission, defined as a Global Assessment of Functioning score greater than 70 sustained for 2 months. Analyses were conducted using lifetest survival estimates. MDD indicates major depressive disorder; OPD, other personality disorders; and BPD, borderline personality disorder.

Comorbidad y curso

Table 2. Comorbid axis II disorders experienced by remitted and non-remitted borderline patients followed prospectively for 6 years

	Remitted BPD patients (%/M)				Non-remitted BPD patients (%/M)				Model		z-score		P-level		Significant covariates
	BL (N = 202)	2-year FU (N = 202)	4-year FU (N = 201)	6-year FU (N = 200)	BL (N = 88)	2-year FU (N = 73)	4-year FU (N = 68)	6-year FU (N = 64)	χ^2 -value	P-level	Dx	Time	Dx	Time	
Odd cluster	23.8 (48)	8.9 (18)	7.0 (14)	2.0 (4)	30.7 (27)	27.4 (20)	10.3 (7)	7.8 (5)	75.4	<0.0001	-2.793	-7.930	0.005	<0.001	Male, lower SES
Paranoid	23.3 (47)	6.9 (14)	5.5 (11)	1.5 (3)	30.7 (27)	26.0 (19)	8.8 (6)	7.8 (5)	73.9	<0.0001	-2.850	-7.984	0.004	<0.001	Lower SES
Schizoid	0.5 (1)	1.0 (2)	2.0 (4)	1.0 (2)	1.1 (1)	1.4 (1)	1.5 (1)	0.0 (0)	4.6	NS	0.181	0.539	NS	NS	Male
Schizotypal	2.0 (4)	1.5 (3)	0.5 (1)	0.0 (0)	3.4 (3)	0.0 (0)	0.0 (0)	1.6 (1)	5.3	NS	-0.782	-2.160	NS	0.031	-
Anxious cluster	62.4 (126)	43.6 (88)	35.3 (71)	20.0 (40)	85.2 (75)	69.9 (51)	76.5 (52)	71.9 (46)	139.1	<0.0001	-7.145	-9.287	<0.001	<0.001	More treatment
Avoidant	36.1 (73)	24.3 (49)	26.4 (53)	15.5 (31)	50.0 (44)	45.2 (33)	52.9 (36)	59.4 (38)	63.0	<0.0001	-4.366	-3.628	<0.001	<0.001	Lower GAF, more treatment
Dependent	41.6 (84)	30.7 (62)	21.4 (43)	7.5 (15)	55.7 (49)	48.0 (35)	48.5 (33)	45.3 (29)	100.6	<0.0001	-4.377	-8.555	<0.001	<0.001	More treatment
Obsessive compulsive	15.8 (32)	4.5 (9)	3.5 (7)	3.0 (6)	12.5 (11)	5.5 (4)	2.9 (2)	1.6 (1)	32.1	<0.0001	0.367	-5.685	NS	<0.001	-
Passive aggressive	18.8 (38)	9.4 (19)	7.0 (14)	2.5 (5)	27.3 (24)	17.8 (13)	19.1 (13)	7.8 (5)	61.3	<0.0001	-2.753	-6.340	0.006	<0.001	Male, lower SES
Self-defeating	21.8 (44)	10.4 (21)	6.5 (13)	1.0 (2)	34.1 (30)	30.1 (22)	27.9 (19)	26.6 (17)	69.4	<0.0001	-5.976	-6.429	<0.001	<0.001	-
Dramatic cluster (without BPD)	27.7 (56)	4.0 (8)	4.5 (9)	4.0 (8)	51.1 (45)	19.2 (14)	19.1 (13)	10.9 (7)	99.6	<0.0001	-5.153	-8.811	<0.001	<0.001	Male, lower SES
Antisocial	18.8 (38)	2.5 (5)	0.0 (0)	2.0 (4)	30.7 (27)	5.5 (4)	0.0 (0)	3.1 (2)	56.9	<0.0001	-1.568	-6.954	NS	<0.001	Male, lower SES, lower GAF
Histrionic	8.4 (17)	1.5 (3)	3.5 (7)	1.5 (3)	15.9 (14)	6.9 (5)	11.8 (8)	6.3 (4)	22.5	<0.0001	-3.324	-3.556	0.001	<0.001	-
Narcissistic	6.9 (14)	0.0 (0)	1.5 (3)	1.5 (3)	19.3 (17)	8.2 (6)	13.2 (9)	1.6 (1)	32.1	<0.0001	-4.202	-4.148	<0.001	<0.001	Male
Sadistic	1.0 (2)	0.0 (0)	0.0 (0)	0.0 (0)	6.8 (6)	1.4 (1)	1.5 (1)	0.0 (0)	19.2	0.0007	-2.151	-2.452	0.031	0.014	Younger, lower GAF

Values in parentheses are *n*-values

GAF, Global Assessment of Functioning; BPD, borderline personality disorder; FU, follow-up; BL, baseline; SES, socioeconomic status.

Tratamiento a largo plazo: Psicoterapia

Table 2. Four Evidence-Based Treatments for Borderline Personality Disorder.*

Type of Therapy	Description
Dialectical behavior therapy	A behavioral therapy that includes both individual and group therapy, involving didactics and homework on mood monitoring and stress management; the best validated and easiest to learn of the psychotherapies, one that teaches the patient how to regulate feelings and behaviors, with the therapist acting as a coach with extensive availability
Mentalization-based therapy	A cognitive or psychodynamic therapy that includes both individual and group therapy, in which the therapist adopts a “not-knowing” stance while insisting that the patient examine and label his or her own experiences and those of others (i.e., mentalizing); emphasis on thinking before reacting (a process that may be central to all effective therapies)
Transference-focused psychotherapy	A twice-weekly individual psychotherapy developed from psychoanalysis that includes interpretation of motives or feelings unknown to the patient and retains a focus on the patient’s misunderstanding of others, especially of the therapist (i.e., transference); the least supportive and hardest to learn of the therapies
General psychiatric management	A once-weekly psychodynamic therapy developed from the APA guidelines ³⁴ and the basic BPD treatment textbook, ² focusing on the patient’s interpersonal relationships but also possibly including family interventions and pharmacologic therapy; the least theory-bound and easiest to learn of the therapies but least well evaluated

* APA denotes American Psychiatric Association, and BPD borderline personality disorder.

Estudios Clínicos Aleatorizados Controlados

	Treatment	Comparison
Bateman and Fonagy ¹⁵⁹	Mentalisation-based treatment in a partial hospital setting	Treatment as usual
Bateman and Fonagy ¹⁵⁸	Mentalisation-based psychodynamic treatment	Structured clinical management
Blum et al ¹⁵⁹	Brief cognitive-behavioural therapy plus treatment as usual	Treatment as usual
Bohus et al ¹⁶¹	Inpatient dialectical behaviour therapy	Treatment as usual
Clarkin et al ¹⁶²	Transference-focused therapy	Dialectical behaviour therapy as supportive therapy
Cottraux et al ¹⁶³	Cognitive-behavioural therapy	Client-centred therapy
Davidson et al ¹⁶⁴	Brief cognitive-behavioural therapy plus treatment as usual	Treatment as usual
Doering et al ¹⁶⁵	Transference-focused therapy	Community treatment by experienced therapists
Farrel et al ¹⁶⁴	Schema-focused therapy plus treatment as usual	Treatment as usual
Giesen-Bloo et al ¹⁶⁵	Schema-focused therapy	Transference-focused therapy
Gregory et al ¹⁶⁶	Dynamic deconstructive therapy	Treatment as usual
Hamed et al ¹⁶⁷	Dialectical behaviour therapy	Community treatment by experts
Koons et al ¹⁶⁴	Dialectical behaviour therapy	Treatment as usual
Linehan et al ¹⁶⁸	Dialectical behaviour therapy	Treatment as usual
Linehan et al ¹⁶⁷	Dialectical behaviour therapy	Treatment as usual
Linehan et al ¹⁶⁷	Dialectical behaviour therapy	Comprehensive validation therapy plus a 12-step substance misuse programme
Linehan et al ¹⁶⁸	Dialectical behaviour therapy	Therapy by experts
McMain et al ¹⁶⁹	Dialectical behaviour therapy	Psychodynamically informed clinical management
Munroe-Blum et al ¹⁷⁰	Psychodynamic therapy	Interpersonal group therapy
Soler et al ¹⁷⁰	Dialectical behaviour therapy skills training	Standard group therapy
Tyrer et al ¹⁷¹	Brief cognitive-behaviour therapy	Treatment as usual
Turner et al ¹⁷²	Dialectical behaviour therapy	Client-centred therapy
Verheul et al ¹⁷³	Dialectical behaviour therapy	Treatment as usual
Weinberg et al ¹⁷³	Brief cognitive-behavioural therapy plus treatment as usual	Treatment as usual

Table 2: Randomised controlled trials of psychotherapy in patients with borderline personality disorder

Leicshering et al., The Lancet 2011

Terapias psicodinámicas

1. MENTALIZATION-BASED TREATMENT. (Bateman and Fonagy ,1999)

Objetivo: aumentar la curiosidad y habilidad en la identificación de sentimientos y pensamientos y los de otras personas. (dificultades en el apego temprano). (Bateman y Fonagy Am J Psych 1999-2000-2003-2006

- 18 meses de seguimiento: reducción de actos de auto-agresión y suicida, días de hospitalizaciones, uso de medicamentos psicotrópicos, ansiedad y síntomas depresivos, y el funcionamiento psicosocial.
- 5-años de seguimiento: suicidio, síntomas TLP, uso de servicios, uso de medicación, GAF por encima de 60, y el estatus profesional.
- Sin embargo, el funcionamiento profesional es inferior al óptimo esperado

2. TRANSFERENCE-FOCUSED PSYCHOTHERAPY. (conceptualización de Kernberg)

Objetivo: reducir el comportamiento autodestructivo a través de la modificación de las representaciones del yo y otras personas (Clarkin Am J PSYC 2007; Doering et al, Br J Psych 2010)

- 1-3-años de seguimiento: (Clarkin et al, 2007) : depresión, ansiedad, funcionamiento global, y funcionamiento social, tendencias suicidas, ira y impulsividad, irritabilidad, asalto verbal, y el asalto directo, apego más seguro y una mayor capacidad reflexiva (Levy et al, 2006.)

Terapias cognitivas comportamentales

1. SCHEMA-FOCUSED THERAPY. (Jeffrey Young , 2003).

Objetivo: El cambio se logra a través de una amplia gama de comportamiento, y técnicas que se centran en la relación terapéutica, la vida cotidiana fuera de la terapia, y las experiencias pasadas (incluyendo experiencias traumáticas). La recuperación de SFT se logra cuando los esquemas disfuncionales ya no controlan la vida del paciente. (Giesen-Bloo Arch Gen Psych 2006).

- 3-años de seguimiento: la psicopatología límite, la psicopatología en general, la calidad de vida. Una reducción significativamente mayor en la gravedad de los síntomas en seis de los nueve criterios DSM-IV para el TLP (cada uno de los síntomas de tipo cognitivo, impulsivo e interpersonales): alteración de la identidad, la disociación / paranoia, actos auto destructivos, impulsividad, miedo al abandono, y relaciones tormentosas. Sin embargo, no hay mejoras significativas en ninguno de los tres criterios DSM-IV para los síntomas afectivos del TLP : la ira, el vacío, o cambios de humor.

2. DIALECTICAL BEHAVIORAL THERAPY. (Linehan , 1993)

Objetivo: manejar la desregulación emocional. (Linehan , Arch Gen Psych 2006-1993-1994)

- 1 año de seguimiento: la reducción de comportamiento parasuicida (automutilación e intentos de suicidio), significativamente menos días en el hospital.

- 2 años de seguimiento: menos intentos de suicidio, menos ira, y mejor ajuste social, significativamente menos días de hospitalización psiquiátrica.

Terapia dialetico-conductual: riesgo de suicidio a 2 años de seguimiento






Figure 3. Survival analysis for time to first suicide attempt. The treatment period ended at 365 days, and the follow-up period ended at 730 days. CTBE indicates community treatment by experts; DBT, dialectical behavior therapy.

Terapia dialetico-conductual: el papel de los síntomas disociativos




Similitudes entre las psicoterapias



La finalización del tratamiento y los factores asociados con el *drop-out* en la psicoterapia

Table 3. Meta-analyses of completion rates in psychotherapy for borderline personality disorder – intervention length 12 months or longer



CBT, cognitive behaviour therapy; DBT, dialectical behaviour therapy; DDP, dynamic deconstructive psychotherapy; MBT, mentalisation-based therapy; TFP, transference-focused therapy.

Tratamiento farmacológico

	Treatment	Mean dose
Bogenschutz et al ⁹⁵	Olanzapine vs placebo	6-9 mg per day
de la Fuente et al ⁹²	Carbamazepine vs placebo	Blood concentration 6.4-7.1 µg/mL
Frankenburg et al ⁹²	Sodium valproate vs placebo	850 mg per day
Goldberg et al ⁹⁷	Tiotixene vs placebo	8.7 mg per day
Hollander et al ⁹¹	Sodium valproate vs placebo	Blood concentration 64.6 µg/mL
Hollander et al ⁹⁴	Sodium valproate vs placebo	1325 mg per day
Leone et al ⁹⁸	Loxapine vs placebo	14.4 mg per day
Leone et al ⁹⁸	Chlorpromazine vs placebo	110 mg per day
Pascual et al ¹⁰⁰	Ziprasidone vs placebo	81 mg per day
Reich et al ⁹⁶	Lamotrigine vs placebo	25-275 mg per day
Rinne et al ⁹⁴	Fluvoxamine vs placebo	150 mg per day
Salzman et al ⁹⁵	Fluoxetine vs placebo	40 mg per day
Schulz et al ⁹⁷	Olanzapine vs placebo	2.5-20 mg per day
Shafti and Shahveisi ⁹⁸	Olanzapine vs haloperidol	2.5-10 mg per day
Soloff et al ⁹⁴	Haloperidol vs amitriptyline vs placebo	4.8 mg per day; 149.1 mg per day
Soloff et al ⁹³	Haloperidol vs phenelzine sulfate vs placebo	3.9 mg per day; 60-45 mg per day
Zanarini et al ⁹⁹	Olanzapine vs placebo	5.3 mg per day
Zanarini et al ⁹⁵	Omega-3 fatty acids vs placebo	1 mg per day
Zanarini et al ⁹⁵	Olanzapine vs fluoxetine vs olanzapine plus fluoxetine	3.3 mg per day; 15.0 mg per day; 3.2 mg per day plus 12.7 mg per day
Ziegenhorn et al ⁹⁹	Clonidine vs placebo	0.45 mg per day

Table 1: Randomised controlled trials of pharmacotherapy in patients with borderline personality disorder

Leicshering et al., The Lancet 2011

